Volume 35, Issue 9 (12-2024)
Studies in Medical Sciences 2024, 35(9): 772-778 |
Back to browse issues page
Ethics code: IR.UMSU.REC.1400.338
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Soleimany A, Hajizadeh R, Manghor Kordestani S, behzadi F. INVESTIGATING THE RELATIONSHIP BETWEEN NT-PRO BNP AND IN-HOSPITAL OUTCOME OF COVID-19 PATIENTS ADMITTED IN THE INTENSIVE CARE UNIT (ICU). Studies in Medical Sciences 2024; 35 (9) :772-778
URL: http://umj.umsu.ac.ir/article-1-6339-en.html
URL: http://umj.umsu.ac.ir/article-1-6339-en.html
Assistant Professor of Cardiovascular Diseases, Department of Cardiovascular Diseases, Urmia University of Medical Sciences, Urmia, Iran (Corresponding Author) , hajizadh.reza@gmail.com
Abstract: (413 Views)
Background & Aims: COVID-19 infection is associated with multiple cardiovascular complications that can impact mortality in patients admitted to intensive care units. This study aimed to investigate the relationship between NT-pro BNP levels and in-hospital outcomes (discharge or death) and changes in left ventricular ejection fraction (LVEF) in COVID-19 patients admitted to intensive care units.
Materials and Methods: A cross-sectional study was conducted on 56 patients with PCR-confirmed COVID-19 and radiological evidence. Patients with a history of previous cardiovascular disease were excluded from the study. NT-pro BNP levels were measured within the first 24 hours of admission, and their association with LVEF and hospital outcomes was analyzed.Results: The mean NT-Pro BNP protein level in discharged COVID-19 patients was 1997.04 ± 456.72 Pg/mL, and in deceased patients was 4417.17 ± 1657.67 Pg/mL (P = 0.04).Discussion and
Conclusion: The results of this study showed that elevated NT-pro BNP levels can be used as a predictive marker to identify patients at risk of death in intensive care units. Further studies are recommended to determine the clinical certainty of this indicator.
Materials and Methods: A cross-sectional study was conducted on 56 patients with PCR-confirmed COVID-19 and radiological evidence. Patients with a history of previous cardiovascular disease were excluded from the study. NT-pro BNP levels were measured within the first 24 hours of admission, and their association with LVEF and hospital outcomes was analyzed.Results: The mean NT-Pro BNP protein level in discharged COVID-19 patients was 1997.04 ± 456.72 Pg/mL, and in deceased patients was 4417.17 ± 1657.67 Pg/mL (P = 0.04).Discussion and
Conclusion: The results of this study showed that elevated NT-pro BNP levels can be used as a predictive marker to identify patients at risk of death in intensive care units. Further studies are recommended to determine the clinical certainty of this indicator.
Keywords: COVID-19, NT-pro BNP, Left Ventricular Ejection Fraction (LVEF), Hospital Outcome, Biomarkers, Prognosis
Type of Study: Research |
Subject:
قلب وعروق بزرگسالان
References
1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507-13. [DOI:10.1016/S0140-6736(20)30211-7] [PMID]
2. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 2020;14(4):395-403. [DOI:10.1016/j.dsx.2020.04.018] [PMID] []
3. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020;5(7):802-10. [DOI:10.1001/jamacardio.2020.0950] [PMID] []
4. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020;5(7):811-8. [DOI:10.1001/jamacardio.2020.1017] [PMID] []
5. Wang D et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020;323(11):1061-9. [DOI:10.1001/jama.2020.1585] [PMID] []
6. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015;313(3):264-74. [DOI:10.1001/jama.2014.18229] [PMID] []
7. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091 . [DOI:10.1136/bmj.m1091] [PMID] []
8. Nowak A, Breidthardt T, Christ-Crain M, Bingisser R, Meune C, Tanglay Y, et al. Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia. Chest 2012;141(4):974-82. [DOI:10.1378/chest.11-0824] [PMID]
9. Pranata R, Huang I, Lukito AA, Raharjo SB. Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis. Postgrad Med J 2020;96(1137):387-91. [DOI:10.1136/postgradmedj-2020-137884] [PMID] []
10. Luchner A, Hengstenberg C, Löwel H, Trawinski J, Baumann M, Riegger GA, et al. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension 2002;39(1):99-104. [DOI:10.1161/hy0102.100537] [PMID]
11. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89(7):745-51. [DOI:10.1136/heart.89.7.745] [PMID] []
12. Lin SC, Tsai YJ, Huang CT, Kuo YW, Ruan SY, Chuang YC, et al. Prognostic value of plasma N-terminal pro B-type natriuretic peptide levels in pneumonia patients requiring intensive care unit admission. Respirology 2013;18(6):933-41. [DOI:10.1111/resp.12096] [PMID]
13. Jeong KY, Kim K, Kim TY, Lee CC, Jo SO, Rhee JE, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia. Emerg Med J 2011;28(2):122-7. [DOI:10.1136/emj.2009.089383] [PMID]
14. Fernandez JF, Restrepo MI. Is N-terminal pro-B-type natriuretic peptide ready for 'prime time' in severe pneumonia? Respirology 2013;18(6):889-90. [DOI:10.1111/resp.12134] [PMID] []
15. Akpınar EE, Hoşgün D, Akpınar S, Ateş C, Baha A, Gülensoy ES, et al. Do N-terminal pro-brain natriuretic peptide levels determine the prognosis of community acquired pneumonia? J Bras Pneumol 2019;45(4):e20180417 . [DOI:10.1590/1806-3713/e20180417] [PMID] []
16. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect 2020;22(2):72-3. [DOI:10.1016/j.micinf.2020.02.006] [PMID] []
17. Rath D, Petersen-Uribe Á, Avdiu A, Witzel K, Jaeger P, Zdanyte M, et al. Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection. Clin Res Cardiol 2020;109(12):1491-9. [DOI:10.1007/s00392-020-01683-0] [PMID] []
18. van den Heuvel FMA, Vos JL, Koop Y, van Dijk APJ, Duijnhouwer AL, de Mast Q, et al. Cardiac function in relation to myocardial injury in hospitalised patients with COVID-19. Neth Heart J 2020;28(7-8):410-7. [DOI:10.1007/s12471-020-01458-2] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
